- Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
Jingpei Li et al, 2020, Frontiers in Oncology CrossRef - Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases
Dimitra Stefanou et al, 2016, Oncology Letters CrossRef - A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
null null et al, 2018, International Journal of Clinical Oncology CrossRef - Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis
Musen Wang et al, 2021, Medicine CrossRef - Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer
Hiroaki Ikesue et al, 2015, Biological & Pharmaceutical Bulletin CrossRef - Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation
Takayasu Kurata et al, 2017, Genes & Cancer CrossRef - Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
Toshirou Fukushima et al, 2018, Cancer Chemotherapy and Pharmacology CrossRef - Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Yasuhiro Tsutani et al, 2018, BMC Cancer CrossRef